p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1‐NF‐κB pathway in human ovarian cancer cells

Platinum‐based therapeutic strategies have been widely used in ovarian cancer treatment. However, drug resistance has greatly limited therapeutic efficacy. Recently, tolerance to cisplatin has been attributed to other factors unrelated to DNA. p62 (also known as SQSTM1) functions as a multifunctiona...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Sci
Egile Nagusiak: Yan, Xiao‐Yu, Zhang, Yu, Zhang, Juan‐Juan, Zhang, Li‐Chao, Liu, Ya‐Nan, Wu, Yao, Xue, Ya‐Nan, Lu, Sheng‐Yao, Su, Jing, Sun, Lian‐Kun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5497928/
https://ncbi.nlm.nih.gov/pubmed/28498503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13276
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak